Israel’s Oramed (Nasdaq: ORMP) has announced positive top-line results from a Phase IIb study to test the safety and efficacy of its oral insulin capsule (ORMD-0801) in patients with type 2 diabetes.
The study’s primary objective, a significant reduction of weighted mean night-time glucose, was successfully achieved.
Nadav Kidron, chief executive of Oramed, said: “This demonstration of safe and effective oral insulin delivery represents a transformative event in the treatment of type 2 diabetes. We are delighted with the results and look forward to moving into Phase III trials.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze